Peptides for immune & inflammation.

Immune peptides sit on a foundation of genuine biology. Antimicrobial peptides are part of innate immunity across essentially all multicellular life, they kill bacteria through mechanisms that are hard to develop resistance against, and they have been studied seriously as an answer to antibiotic resistance for decades. The interest is not manufactured.

Translating that into medicine has proved much harder than the biology suggests. Antimicrobial peptides are frequently toxic to human cells at concentrations near the ones that kill bacteria, they are degraded rapidly in the body, and systemic administration has repeatedly run into a narrow therapeutic window. Where these compounds have reached clinical use it has usually been topical or local rather than systemic, which reflects those limits rather than a lack of effort.

The immune-modulating compounds work differently, aiming to nudge immune function rather than kill pathogens directly. Thymosin alpha-1 is the most developed of these, used clinically in a number of countries for chronic hepatitis and as an immune adjunct, though it remains unapproved in the United States. The thymus-derived bioregulators carry the same single-source caveat as their longevity counterparts, since much of that literature comes from one research group.

The general principle worth holding onto in this category is that modulating immune function is not straightforwardly good. The immune system is a balance, and pushing it in either direction has consequences. A compound described as boosting immunity is describing an intervention in a regulated system, and the relevant question is always what specifically it does, in whom, and what happens when it is sustained.